Loading...
Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-guided radiotherapy without hormone therapy.
Berlin, A Murgic, J Hosni, A Pintilie, M Salcedo, A Fraser, M Kamel-Reid, S Zhang, J Wang, Q Ch'ng, C
Berlin, A
Murgic, J
Hosni, A
Pintilie, M
Salcedo, A
Fraser, M
Kamel-Reid, S
Zhang, J
Wang, Q
Ch'ng, C
Citations
Altmetric:
Abstract
The NCCN has recently endorsed the stratification of intermediate-risk prostate cancer (IR-PCa) into favorable and unfavourable subgourps, and recommend the addition of androgen deprivation therapy (ADT) to radiotherapy (RT) for unfavorable IR-PCa. Recently, more accurate prognostication was demonstrated by integrating a 22-feature genomic classifier (GC) to the NCCN stratification system. Here, we test the utility of the GC to better identify IR-PCa patients who are sufficiently treated by RT alone.
Description
Date
2018-08-28
Publisher
Collections
Keywords
Type
Article
Citation
Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-guided radiotherapy without hormone therapy. 2018, Int J Radiat Oncol Biol Phys